Castle Biosciences (CSTL) Non-Current Debt (2018 - 2026)

Castle Biosciences has reported Non-Current Debt for 6 years, with the latest figure at $10.1 million in Q2 2026.

• Quarterly Non-Current Debt changed 0.35% year-over-year to $10.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $10.1 million (changed 0.35% YoY) and the FY2025 annual result came in at $10.1 million, changed 0.34% from the prior year.
• Non-Current Debt held at $10.1 million in Q2 2026 per CSTL's latest filing, from $10.1 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $10.1 million in Q2 2026 and troughed at $10.0 million in Q1 2024.
• A 3-year average of $10.0 million and a median of $10.0 million in 2025 frame the typical range for Non-Current Debt.
• The sharpest annual moves came in 2025 and 2026: Non-Current Debt rose 0.32% in 2025, then increased 0.35% in 2026.
• Over 3 years, Non-Current Debt stood at $10.0 million in 2024, then climbed by 0.34% to $10.1 million in 2025, then climbed by 0.18% to $10.1 million in 2026.
• According to Business Quant data, Non-Current Debt over the past three periods registered $10.1 million, $10.1 million, and $10.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.